The United Laboratories Int'l Hldg Ltd is an investment holding company operating in the pharmaceutical sector. The group focuses on the research, development, and commercialization of new and generic drugs, with a particular emphasis on the GLP-1 target for diabetes and obesity treatments. Key products include Liraglutide Injection, which was approved for marketing during the year, and Semaglutide Injection, which has entered the production application stage. The company maintains a pipeline of Class I new drug candidates, including UBT251 Injection and UBT37034 Injection, which are in various stages of clinical trials for indications such as overweight, obesity, diabetes, metabolic dysfunction-associated steatohepatitis, and chronic kidney disease. The group serves the Chinese market and is expanding internationally, with clinical trials for UBT37034 Injection approved in both China and the United States. The company invests in R&D to advance new drug development, out-licensing, and product registration.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage tul.com.cn
Sector Healthcare IR page ir.tul.com.cn
Tags
innovative drugs, generic drugs, glp-1, diabetes, obesity, mash, chronic kidney disease, biological products, clinical trials, pharmaceutical r&d, Liraglutide Injection, Semaglutide Injection, UBT251 Injection, UBT37034 Injection
Press page —

Metrics

Valuation  
Market cap HK$ 14.08B
Market cap (USD) $ 1.794B
P/E 5.74
PEG 0.59
P/BV 0.66
P/S 1.01
P/OCF 6.69
P/FCF —
Dividend yield 4.2%
Turnover / mcap 0.10%
Returns  
ROE 13.1%
ROI 10.7%
ROIC 10.7%
Profit margin 15.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 9.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 6.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 13.211B 13.759B 13.74B 11.334B 9.703B 8.772B 8.393B 7.511B 6.827B 6.069B 6.258B 6.388B 6.041B 5.751B 5.273B 5.664B
Net profit 2.086B 2.66B 2.701B 1.581B 988.098M 702.989M 641.764M 682.928M 81.758M -267.518M 89.756M 541.793M 37.941M 132.656M 85.851M 848.543M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 14.23 — 6.79 — — 6.46 3.86 4.14 5.44 — — — — — — —
Price performance 12m — — — — — 0.68 -0.1 -0.25 — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

The United Laboratories Int'l Hldg Ltd (ticker 3933), listed in Hong Kong.

Company History

Date Change Detail
Jun 30, 2017 Reporting currency Its HK reports are in CNY instead of HKD from this period. Earlier figures are shown in CNY, converted at each period end's exchange rate.

ETFs Holding The United Laboratories Int'l Hldg Ltd

ETF Weight in ETF Shares Market value As of
OZEM 2.05% 1,222,000 $ 1.143M Nov 17, 2026
AVDV 0.10% 19,784,000 $ 18.55M Nov 16, 2026
AVDS 0.04% 138,000 $ 129.391K Nov 16, 2026
DFIS 0.02% 1,430,000 $ 1.408M Nov 12, 2026
DISV 0.02% 832,000 $ 819.31K Nov 12, 2026
DFIC 0.01% 1,860,000 $ 1.832M Nov 12, 2026
AVDE 0.01% 1,616,000 $ 1.515M Nov 16, 2026
AVIV 0.01% 120,000 $ 112.514K Nov 16, 2026
DFAX 0.01% 1,048,500 $ 1.033M Nov 12, 2026
DFAI 0.01% 1,094,000 $ 1.077M Nov 12, 2026